AstraZeneca: Targeted lung cancer drug Teresa? Indications for first-line combined chemotherapy for advanced non-small cell lung cancer with EGFR mutation approved in China
我放心你带套猛
发表于 2024-6-26 15:36:13
223
0
0
According to AI News, AstraZeneca announced on June 26 that the National Medical Products Administration of China officially approved Teresa& on June 18, 2024; reg; The combination of pemetrexed and platinum based chemotherapy drugs is a first-line treatment for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 (L858R) displacement mutation, commonly known as TAGRISSO® or commonly known as ositinib mesylate tablets.
CandyLake.com 系信息发布平台，仅提供信息存储空间服务。
声明：该文观点仅代表作者本人，本文不代表CandyLake.com立场，且不构成建议，请谨慎对待。
声明：该文观点仅代表作者本人，本文不代表CandyLake.com立场，且不构成建议，请谨慎对待。
转播
猜你喜欢
- Boeing has discovered defects in 737 Max bolts, and FAA is closely monitoring targeted inspections
- Baishime Squibb's original albumin paclitaxel has been approved as a new indication in China
- Innovation Drug Enterprises on the Science and Technology Innovation Board Welcoming a Harvest Year: Baekje Shenzhou PD-1 New Indications Accepted by FDA
- JAK1 inhibitor Xibico? New indications for age expansion approved in China
- BeiGene Terezumab has been approved by the European Commission for the treatment of non-small cell lung cancer
- Anjin small cell lung cancer treatment drug approved by FDA: can reduce tumor size and prolong lifespan
- Dialogue with Qian Jing, Vice President of Jingke Energy: Market oriented ability is crucial for the third and fourth quarters of the industry to show signs of recovery
- AstraZeneca lung cancer targeted drug Teresa has been approved for new indications in China
- AstraZeneca Imfinzi approved by FDA for postoperative adjuvant therapy in non-small cell lung cancer patients
- Pfizer's innovative targeted therapy drug Taizena has been approved in China
